1. Volume 142, Issue 4, Pages 790-795 (April 2012)
Effect of IL28B Genotype on Early Viral Kinetics During Interferon-Free Treatment of Patients With Chronic Hepatitis C 
Tom W. Chu, Rohit Kulkarni, Edward J. Gane, Stuart K. Roberts, Catherine Stedman, Peter W. Angus, Brett Ritchie, Xiao-Yu Lu, David Ipe, Uri Lopatin, Soren Germer, Victor A. Iglesias, Robert Elston, Patrick F. Smith, Nancy S. Shulman 
Gastroenterology 
Volume 142, Issue 4, Pages (April 2012)
DOI: /j.gastro
Copyright © 2012 AGA Institute Terms and Conditions

2. Figure 1
Study design of the INFORM-1 trial. Patients with chronic HCV infection, including treatment naive, interferon treatment failure (partial responder and relapse), and interferon null responders, were randomized to either active study drugs or matching placebo by cohort. Patients received interferon-free combinations of mericitabine and danoprevir at increasing doses. The patients were allowed to initiate pegylated interferon/ribavirin treatment after completion of active study drug dosing.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2012 AGA Institute Terms and Conditions

3. Figure 2
Mean change in serum HCV RNA level between study days 1 and 14 by rs genotype in all patients in cohorts C–G (n = 45) who received 13 days of dual oral combination therapy with mericitabine plus danoprevir.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2012 AGA Institute Terms and Conditions

4. Figure 3
Mean change in serum HCV RNA level between study days 1 and 14 by rs genotype in all patients in the 2 highest dose cohorts (F and G; n = 15) in which patients received 13 days of dual oral combination therapy with mericitabine 1000 mg twice daily plus danoprevir 900 mg twice daily.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2012 AGA Institute Terms and Conditions

5. Figure 4
Early viral kinetics during combination treatment (ie, day 1 to day 14) by IL28B genotype for all subjects in active arm from cohorts C to G who received 13 days of dual oral combination therapy with mericitabine plus danoprevir.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2012 AGA Institute Terms and Conditions